

**IN THE CLAIMS:**

The present listing of the claims will replace all previous claim listings as follows:

1. (Currently amended) A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving agent incorporated into a wound-contacting layer of a material that exhibits suitable permeability for wound exudates, said wound-contacting layer also having a thickness of between about 0.5 mm and about 1.5 mm and being easily removable from the wound, wherein the device has a maximum absorption of ~~0.2~~ 0.1 g/cm<sup>2</sup> to promote moist wound healing.

2. (Cancelled)

3. (Previously presented) The device according to claim 1, wherein the pain-relieving agent is an anti-inflammatory pain-relieving agent.

4. (Cancelled)

5. (Previously presented) The device according to claim 1, wherein the device has a maximum absorption of  $0.05 \text{ g/cm}^2$ .

6. (Previously presented) The device according to claim 1, wherein the device is in the form of a sheet-like layer.

7. (Previously presented) The wound care device according to claim 6, wherein the layer is prepared from a web, a net, a knit, a woven or a non-woven fabric, a permeable or perforated film or a foam or a hydrogel.

8. (Previously presented) The device according to claim 1, wherein at least 50% w/w of the pain relieving agent is released during the first 12 hours after application.

9. (Previously presented) The device according to claim 1, wherein at least 50% w/w of the pain relieving agent is released during the first 6 hours after application.

10. (Previously presented) The device according to claim 1, wherein at least 75% w/w of the pain relieving agent is released

during the first 24 hours after application.

11. (Previously presented) The device according to claim 1, wherein at least 75% w/w of the pain relieving agent is released during the first 12 hours after application.

12. (Previously presented) The device according to claim 1, wherein at least 75% w/w of the pain relieving agent is released during the first 6 hours after application.

13. (Previously presented) The device according to claim 1, wherein at least 90% w/w of the pain relieving agent is released during the first 24 hours after application.

14. (Previously presented) The device according to claim 1, wherein at least 90% w/w of the pain relieving agent is released during the first 12 hours after application.

15. (Previously presented) The device according to claim 1, wherein at least 90% w/w of the pain relieving agent is released during the first 6 hours after application.

16.-18. (Cancelled).

19. (Previously presented) The device according to claim 1, wherein the pain relieving agent is a NSAID.

20. (Previously presented) The device according to claim 1, wherein the pain relieving agent is ibuprofen.

21.-26. (Cancelled).

27. (Previously presented) The wound care device according to claim 7, wherein the device is in the form of an open fabric.

28.. (Previously presented) The wound care device according to claim 27 wherein the composition further comprises a non-stick agent.

29. (Cancelled).

30. (Previously presented) The wound care device according to claim 28, wherein the non-stick agent comprises petrolatum.

31. (Previously presented) The device according to claim 1, wherein at least 50% w/w of the pain-relieving agent is released during the first 24 hours after application.

32. (Previously presented) The wound care device according to claim 1, wherein the wound-contacting layer is coated with a composition comprising the pain relieving agent.

33. (Previously presented) The wound care device according to claim 1, wherein the wound-contacting layer is impregnated with a composition comprising the pain relieving agent.

34. (Previously presented) The wound care device according to claim 1, wherein the device is constructed such that the pain relieving agent is released to the wound at a rate that will result in a plasma concentration of pain relieving agent that is incapable of causing any systemic effect.

35. (Previously presented) A wound care dressing comprising a wound-contacting layer in the form of the device of claim 1 and further comprising an absorbent layer.

36. (Previously presented) The wound care dressing according to claim 1, wherein the amount of the active pain relieving agent in the device is below the daily unit dose for systemic treatment.

37. (Previously presented) The device according to claim 36, wherein the pain-relieving agent is an anti-inflammatory pain-relieving agent.

38. (Cancelled)

39. (Previously presented) The device according to claim 1, wherein the device has a maximum absorption of  $0.075 \text{ g/cm}^2$ .